|Bid||6.56 x 2200|
|Ask||6.57 x 3100|
|Day's Range||6.54 - 6.99|
|52 Week Range||3.34 - 10.88|
|Beta (5Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.21|
With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO. This study further expands our approach to displacing single-agent chemotherapy in later lines of treatment in ovarian cancer.
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 10.53% and -7.15%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?